How should I cycle it
New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Journal of Endocrinology and Metabolism , 4 (3), 64-77
As more individuals recognize the dual role of GLP-1 therapies in reducing body weight and lowering the risk of major cardiovascular events, demand for these medications continues to expand across diverse patient groups
Factors: Treatment For Hair Loss Due to GLP-1 Ozempic, Wegovy, and Zepbound have changed how millions of Americans lose weight, but a growing number of patients are also losing hair
however, similar pigment changes may also be seen in malignant conditions such as melanoma, so a doctor may need to examine it to distinguish between the two
